Literature DB >> 28336058

Large (9 mm) Deep Anterior Lamellar Keratoplasty with Clearance of a 6-mm Optical Zone Optimizes Outcomes of Keratoconus Surgery.

Massimo Busin1, Pia Leon2, Yoav Nahum3, Vincenzo Scorcia4.   

Abstract

PURPOSE: To evaluate the outcomes of a 9-mm deep anterior lamellar keratoplasty (DALK) with removal of the deep stroma limited to the central 6-mm optical zone.
DESIGN: Prospective, noncomparative, interventional case series. PARTICIPANTS: A total of 80 consecutive keratoconic eyes without deep stromal scarring, with at least 1 postoperative examination 1 month after complete suture removal. INTERVENTION: A standardized DALK was performed, including (1) deep trephination of the recipient bed 450 to 550 μm in depth and 9 mm in diameter; (2) pneumatic dissection; (3) debulking of approximately 80% of the anterior stroma; (4) removal of the deep stroma (bubble roof) from a central 6-mm optical zone; and (5) transplantation of a 9-mm anterior corneal lamella cut by microkeratome-assisted dissection (400-μm head) and sutured with a double running 10-0 nylon suture. MAIN OUTCOME MEASURES: Success rate and type of pneumatic dissection obtained; best spectacle-corrected visual acuity (BSCVA), refractive astigmatism (RA), and topographic astigmatism (TA), central corneal thickness (CCT) and endothelial cell density 12 months postoperatively; and intraoperative and postoperative complications.
RESULTS: Pneumatic dissection created a "big bubble" in 67 of 80 eyes (83.7%), all of them but 1 (1.5%) being of type 1 according to the classification by Dua et al. After complete suture removal, BSCVA averaged 0.09±0.72 logarithm of the minimum angle of resolution (logMAR) and was ≥20/20 in 28 eyes (35%), ≥20/25 in 54 eyes (67.5%), and ≥20/40 in 76 eyes (95%); RA averaged 3.10±1.30 diopters (D), with 73 eyes (91%) within 4.5 D and none above 6 D; regular TA was detected in 72 eyes (90%); mean CCT was 492±62.10 μm; postoperative endothelial cell density averaged 2026±397cells/mm2 with a mean cell loss of 11.2%. Intraoperative complications included loss of suction (n = 1) and perforation (n = 4). No conversion to penetrating keratoplasty was necessary. After surgery, double anterior chamber was observed in 2 cases (2.5%), both managed successfully by air filling of the anterior chamber. Stromal rejection was observed in 6 eyes (7.5%) and was reversed with topical steroids in all cases.
CONCLUSIONS: In keratoconic eyes without deep stromal scars, the combination of a graft larger than conventional ones with limited removal of deep stroma can improve visual and refractive outcomes of DALK, while minimizing the rate of complications.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28336058     DOI: 10.1016/j.ophtha.2017.02.011

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Deep anterior lamellar keratoplasty for keratoconus: Elements for success.

Authors:  Marco Pellegrini; Angeli Christy Yu; Massimo Busin
Journal:  Saudi J Ophthalmol       Date:  2022-07-11

2.  Preliminary Results of a Novel Standardized Technique of Femtosecond Laser-Assisted Deep Anterior Lamellar Keratoplasty for Keratoconus.

Authors:  Andrea Lucisano; Giuseppe Giannaccare; Marco Pellegrini; Federico Bernabei; Angeli Christy Yu; Adriano Carnevali; Laura Logozzo; Giovanna Carnovale Scalzo; Vincenzo Scorcia
Journal:  J Ophthalmol       Date:  2020-09-03       Impact factor: 1.909

Review 3.  Post Penetrating Keratoplasty Ectasia: Incidence, Risk Factors, Clinical Features, and Treatment Options.

Authors:  Antonio Moramarco; Lorenzo Gardini; Danilo Iannetta; Piera Versura; Luigi Fontana
Journal:  J Clin Med       Date:  2022-05-10       Impact factor: 4.964

4.  Corneal Adhesion Possesses the Characteristics of Solid and Membrane.

Authors:  Jiajin Yang; Qiaomei Ren; Dong Zhao; Zhipeng Gao; Xiaona Li; Rui He; Weiyi Chen
Journal:  Bioengineering (Basel)       Date:  2022-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.